Filipa Dourado Sotero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Filipa Dourado Sotero has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Pavão Martins
Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
5 shared publications - Aaron L. Wong
Jefferson Moss Rehabilitation Research Institute, Thomas Jefferson University, Elkins Park, PA, USA; Department of Rehabilitation Medicine, Thomas Jefferson University, Philadelphia, PA, USA
1 shared publication - Alfonso Caramazza
Department of Psychology, Harvard University, Cambridge, MA, USA
1 shared publication - Andreia Costa
Unidade Local de Saúde de São João, Departamento de Neurologia, Porto, Portugal
1 shared publication - Beatriz Stein
Serviço de Neurologia. Hospital de Santa Maria. Unidade de Saúde Local de Santa Maria. Lisboa. & Laboratório de Estudos de Linguagem. Centro de Estudos Egas Moniz. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal
1 shared publication - Bárbara Martins
Serviço de Neurologia Hospital Universitário São João Porto Portugal
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Beyond headache: Cognitive improvement in patients with migraine responding to anti-CGRP monoclonal antibodies or botulinum toxin
Background: Cognitive functioning worsens during migraine attacks and in the interictal period, especially in chronic migraine. This study aims to evaluate whether preventive treatment with anti-CGRP monoclonal antibodies (mAbs) or botulinum toxin (BoNT) improves interictal cognitive performance in migraine patients, and to compare cognitive changes between treatment responders and non-responders, controlling for treatment type. Methods: A two-center prospective longitudinal comparative study of patients with Episodic (EM) or Chronic (CM) migraine receiving either mAbs or BoNT. Participants underwent two comprehensive cognitive evaluations targeting attention/processing speed, executive functions, episodic memory, and language, at baseline (visit 1) and after three to six months of treatment (visit 2). The primary end point was the degree of improvement measured by the z scores of each cognitive domain (adjusted for age and education), from baseline to follow-up, assessed using repeated-measures analysis with time as the within-subject factor and treatment response as the between-subject factor, controlling for treatment group. Treatment response was defined as a decrease in monthly moderate-to-severe headache days of ≥30% in CM or ≥50% in EM at follow-up. Results: One hundred patients were included, and 90 completed the study (median age = 42 years, 96.7% women, 58 (64.4%) with CM, 64 (71.1%) treated with mAbs, and 26 (28.8%) with BoNT. Forty-seven (52.2%) were responders (59.4% in the mAbs group and 34.6% in the BoNT group) after a mean follow-up time of 4.5 months. Improvement in a measure of executive functions (comprising tests of working memory, alternating attention, and phonological fluency) was significantly higher in responders than in non-responders, independently of treatment group. No significant differences between responders and non-responders were observed in episodic memory, language, or processing speed. Among responders, the change in executive function score was not associated with the reduction in monthly moderate-severe headache days or the final number of monthly headache-free days. Conclusions: Performance on measures of executive capacities, may improve in migraine patients after a few months of effective migraine treatment with mAbs or BoNT, regardless of the treatment group. Further research is needed to determine whether this effect augments over time, is associated to the reduction of pre-ictal and post-ictal days and /or to brain networks reorganization.
- 15 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Open AccessBeyond headache: Cognitive improvement in patients with migraine responding to anti-CGRP monoclonal antibodies or botulinum toxin
Background: Cognitive functioning worsens during migraine attacks and in the interictal period, especially in chronic migraine. This study aims to evaluate whether preventive treatment with anti-CGRP monoclonal antibodies (mAbs) or botulinum toxin (BoNT) improves interictal cognitive performance in migraine patients, and to compare cognitive changes between treatment responders and non-responders, controlling for treatment type. Methods: A two-center prospective longitudinal comparative study of patients with Episodic (EM) or Chronic (CM) migraine receiving either mAbs or BoNT. Participants underwent two comprehensive cognitive evaluations targeting attention/processing speed, executive functions, episodic memory, and language, at baseline (visit 1) and after three to six months of treatment (visit 2). The primary end point was the degree of improvement measured by the z scores of each cognitive domain (adjusted for age and education), from baseline to follow-up, assessed using repeated-measures analysis with time as the within-subject factor and treatment response as the between-subject factor, controlling for treatment group. Treatment response was defined as a decrease in monthly moderate-to-severe headache days of ≥30% in CM or ≥50% in EM at follow-up. Results: One hundred patients were included, and 90 completed the study (median age = 42 years, 96.7% women, 58 (64.4%) with CM, 64 (71.1%) treated with mAbs, and 26 (28.8%) with BoNT. Forty-seven (52.2%) were responders (59.4% in the mAbs group and 34.6% in the BoNT group) after a mean follow-up time of 4.5 months. Improvement in a measure of executive functions (comprising tests of working memory, alternating attention, and phonological fluency) was significantly higher in responders than in non-responders, independently of treatment group. No significant differences between responders and non-responders were observed in episodic memory, language, or processing speed. Among responders, the change in executive function score was not associated with the reduction in monthly moderate-severe headache days or the final number of monthly headache-free days. Conclusions: Performance on measures of executive capacities, may improve in migraine patients after a few months of effective migraine treatment with mAbs or BoNT, regardless of the treatment group. Further research is needed to determine whether this effect augments over time, is associated to the reduction of pre-ictal and post-ictal days and /or to brain networks reorganization.
- Open Access
- 23 March 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (3)
Therapeutic dissociation of CGRP-targeted treatments in migraine and complex regional pain syndrome
- 23 March 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (3)
Open AccessTherapeutic dissociation of CGRP-targeted treatments in migraine and complex regional pain syndrome
- Open Access
Dissociation between physical reasoning and tool use in individuals with left hemisphere brain damage
Many everyday tasks, from chopping vegetables to catching a ball, require understanding both how objects respond to physical forces and how to use them effectively. These capacities, tool use and physical reasoning, are often assumed to rely on shared cognitive and neural mechanisms. At some level, this correspondence is expected: using an object typically requires understanding its physical properties. However, both capacities are complex and multicomponential, so the relationship between them may vary across levels of representation and task demands. Here, we asked whether third-person physical reasoning about object dynamics can dissociate from tool use (i.e., performing a tool’s typical action, such as using a hammer to drive a nail) in individuals with left-hemisphere stroke. We tested 11 patients, five of whom showed impairments in tool use. Physical reasoning was assessed using a novel collection of tasks probing judgments about mass, velocity, and timing across static and dynamic scenes. Tool use was evaluated using a classic gesture-to-sight task, a pantomime-based measure in which participants are shown pictures of familiar tools and asked to demonstrate how each would be used. We identified an individual-level dissociation: patient I.A.* showed impairment in gesturing the use of objects despite preserved physical reasoning, often outperforming neurotypical controls. This pattern was complemented by patient N.P., who showed the reverse profile, with intact tool use gestures but difficulties in some physical reasoning tasks. These findings suggest that the ability to reason about the physical world and tool use can dissociate behaviorally and be independently disrupted by brain damage. This challenges the view that physical reasoning and tool use draw on the same underlying cognitive and neural mechanisms and suggests that at least some of their components are distinct.
Open AccessDissociation between physical reasoning and tool use in individuals with left hemisphere brain damage
Many everyday tasks, from chopping vegetables to catching a ball, require understanding both how objects respond to physical forces and how to use them effectively. These capacities, tool use and physical reasoning, are often assumed to rely on shared cognitive and neural mechanisms. At some level, this correspondence is expected: using an object typically requires understanding its physical properties. However, both capacities are complex and multicomponential, so the relationship between them may vary across levels of representation and task demands. Here, we asked whether third-person physical reasoning about object dynamics can dissociate from tool use (i.e., performing a tool’s typical action, such as using a hammer to drive a nail) in individuals with left-hemisphere stroke. We tested 11 patients, five of whom showed impairments in tool use. Physical reasoning was assessed using a novel collection of tasks probing judgments about mass, velocity, and timing across static and dynamic scenes. Tool use was evaluated using a classic gesture-to-sight task, a pantomime-based measure in which participants are shown pictures of familiar tools and asked to demonstrate how each would be used. We identified an individual-level dissociation: patient I.A.* showed impairment in gesturing the use of objects despite preserved physical reasoning, often outperforming neurotypical controls. This pattern was complemented by patient N.P., who showed the reverse profile, with intact tool use gestures but difficulties in some physical reasoning tasks. These findings suggest that the ability to reason about the physical world and tool use can dissociate behaviorally and be independently disrupted by brain damage. This challenges the view that physical reasoning and tool use draw on the same underlying cognitive and neural mechanisms and suggests that at least some of their components are distinct.
- Open Access
- 5 November 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Sex differences in clinical characteristics and treatment patterns in Portuguese headache clinics: A retrospective analysis of 700 patients
Background: Headaches are more prevalent in women, causing male underrepresentation in studies. This study aimed to characterize men with headache at two tertiary headache clinics (one public, one private) and explore sex differences. Methods: Retrospective exploratory study. Sociodemographic and clinical data, including ICHD-3 diagnosis and treatment, were collected from clinical files of patients’ consultations between nov/2023 and nov/2024. Results: Among 700 patients, 112 (16.0%) were men. Men were older at first appointment (48.2 vs 42.6 years, p < 0.001), had later symptom onset (36.0 vs 26.4 years, p < 0.001), more often unfulfilled specific headache diagnostic criteria (10.7% vs 8.3%, p < 0.001) and had higher frequency of trigeminal autonomic cephalalgias (20.4% vs 1.3%, p < 0.001) and cranial neuralgias/facial pain (9.0% vs 2.9%, p = 0.003), the latter explained by a higher age at symptom onset at a regression analysis. Men were more likely to have no preventive medication prescribed (36.6% vs 21.4%, p = 0.001) and less often overused analgesics (10.5% vs 28.1%, p < 0.001). Migraine was the most common diagnosis (42.0% men vs 73.3% women), with less chronic migraine in men (16.7% vs 37.6%, p = 0.004). Conclusions: Findings reveal sex differences in age, diagnoses, and treatment, highlighting the need for sex-focused research and personalized clinical approaches.
- 5 November 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Open AccessSex differences in clinical characteristics and treatment patterns in Portuguese headache clinics: A retrospective analysis of 700 patients
Background: Headaches are more prevalent in women, causing male underrepresentation in studies. This study aimed to characterize men with headache at two tertiary headache clinics (one public, one private) and explore sex differences. Methods: Retrospective exploratory study. Sociodemographic and clinical data, including ICHD-3 diagnosis and treatment, were collected from clinical files of patients’ consultations between nov/2023 and nov/2024. Results: Among 700 patients, 112 (16.0%) were men. Men were older at first appointment (48.2 vs 42.6 years, p < 0.001), had later symptom onset (36.0 vs 26.4 years, p < 0.001), more often unfulfilled specific headache diagnostic criteria (10.7% vs 8.3%, p < 0.001) and had higher frequency of trigeminal autonomic cephalalgias (20.4% vs 1.3%, p < 0.001) and cranial neuralgias/facial pain (9.0% vs 2.9%, p = 0.003), the latter explained by a higher age at symptom onset at a regression analysis. Men were more likely to have no preventive medication prescribed (36.6% vs 21.4%, p = 0.001) and less often overused analgesics (10.5% vs 28.1%, p < 0.001). Migraine was the most common diagnosis (42.0% men vs 73.3% women), with less chronic migraine in men (16.7% vs 37.6%, p = 0.004). Conclusions: Findings reveal sex differences in age, diagnoses, and treatment, highlighting the need for sex-focused research and personalized clinical approaches.
- Open Access
- 3 October 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (1) , 336-340
Can atogepant be a preventive treatment for cluster headache?—Insights from a case series
Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an oral, small‐molecule, CGRP receptor antagonist, which is approved for the preventive treatment of migraine. Here, we describe four case reports of CH (two episodic CH and two chronic CH), unresponsive to previous prophylactic treatments, who responded to daily atogepant (60 mg). Chronic CH cases were refractory to subcutaneous galcanezumab. In one case, a reduction to atogepant (30 mg daily) resulted in recurrence of headache attacks, which subsided on reintroduction of the initial dose. No serious adverse effects were reported. Despite the limited number of cases and the open retrospective design, our case series suggests atogepant as a possible prophylactic treatment for CH. Further research on CGRP signaling in CH and the implementation of well‐designed clinical trials are necessary.
- 3 October 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (1) , 336-340
Open AccessCan atogepant be a preventive treatment for cluster headache?—Insights from a case series
Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an oral, small‐molecule, CGRP receptor antagonist, which is approved for the preventive treatment of migraine. Here, we describe four case reports of CH (two episodic CH and two chronic CH), unresponsive to previous prophylactic treatments, who responded to daily atogepant (60 mg). Chronic CH cases were refractory to subcutaneous galcanezumab. In one case, a reduction to atogepant (30 mg daily) resulted in recurrence of headache attacks, which subsided on reintroduction of the initial dose. No serious adverse effects were reported. Despite the limited number of cases and the open retrospective design, our case series suggests atogepant as a possible prophylactic treatment for CH. Further research on CGRP signaling in CH and the implementation of well‐designed clinical trials are necessary.
- Open Access
- 17 September 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (3) , 218-220
Disentangling a Functional Speech Disorder in the Context of another Neurological Disease: A Case Report
This clinical case describes the communication profile of a functional speech disorder. A 48-year-old woman was admitted to the emergency service due to sudden changes in speech, generalized dystonia and gait ataxia. Magnetic resonance imaging showed multiple supra and infratentorial inflammatory lesions involving the posterior occipito-temporal lobes bilaterally, frontal convexity bilaterally, insula and paramedian frontal cortex on the left, diencephalon, rhombencephalon. On the third day, a speech pathology evaluation was conducted, revealing inconsistencies in speech: repetitions of initial sounds, without characteristics of an acquired stutter, a clenched articulation, not justified by an orofacial motor disorder, an inconsistent pattern in voice and prosody. Three days later, another assessment was carried out, showing a significant improvement in speech intelligibility. There was a marked variability in speech features defects found over the days, as well as in their severity. These behaviors appear simultaneously with a speech pattern that is not justified by any of the neurological lesions found.
- 17 September 2025
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 39 (3) , 218-220
Open AccessDisentangling a Functional Speech Disorder in the Context of another Neurological Disease: A Case Report
This clinical case describes the communication profile of a functional speech disorder. A 48-year-old woman was admitted to the emergency service due to sudden changes in speech, generalized dystonia and gait ataxia. Magnetic resonance imaging showed multiple supra and infratentorial inflammatory lesions involving the posterior occipito-temporal lobes bilaterally, frontal convexity bilaterally, insula and paramedian frontal cortex on the left, diencephalon, rhombencephalon. On the third day, a speech pathology evaluation was conducted, revealing inconsistencies in speech: repetitions of initial sounds, without characteristics of an acquired stutter, a clenched articulation, not justified by an orofacial motor disorder, an inconsistent pattern in voice and prosody. Three days later, another assessment was carried out, showing a significant improvement in speech intelligibility. There was a marked variability in speech features defects found over the days, as well as in their severity. These behaviors appear simultaneously with a speech pattern that is not justified by any of the neurological lesions found.
- 12 August 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (4) , 331-339
Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: A systematic review
Background: Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder. Clinical features encompass a broad spectrum of movement disorders, psychiatric and cognitive symptoms, often progressing to dementia and imposing a substantial burden on patients and their families. While cholinesterase inhibitors and memantine are often used for symptomatic treatment of Alzheimer's Disease and other dementias, there is currently no approved medication for treating cognitive symptoms in HD. Objective: We aim to review, summarize, and appraise evidence from the literature for the use of cholinesterase inhibitors and memantine in the treatment of cognitive symptoms in patients with HD. Methods: A searched was conducted in PubMed and SCOPUS, from inception until February 2024, for Randomized Clinical Trials (RCTs), open-label, and case-control studies. Quality appraisal was performed using ROBINS-I and ROB2 for non-randomized studies and RCTs, respectively. Results: Five eligible studies (three RCTs, one extension study, and one retrospective case-control), exploring the use of rivastigmine (n = 3), memantine (n = 1), and donepezil (n = 1) were found. Only two had a follow-up period longer than eight months. Previous cognitive functioning was not specified in three out of five studies. Cognitive measures varied widely, with Unified Huntington's Disease Rating Scale and Mini-Mental State Exam being used more frequently. None of the studies showed a significant improvement in cognitive function. Side effects occurred in up to 50% of patients and were usually considered mild. Conclusions: There is insufficient evidence in the literature to support the use of cholinesterase inhibitors or memantine for cognitive symptoms in patients with HD.
- 12 August 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (4) , 331-339
Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: A systematic review
Background: Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder. Clinical features encompass a broad spectrum of movement disorders, psychiatric and cognitive symptoms, often progressing to dementia and imposing a substantial burden on patients and their families. While cholinesterase inhibitors and memantine are often used for symptomatic treatment of Alzheimer's Disease and other dementias, there is currently no approved medication for treating cognitive symptoms in HD. Objective: We aim to review, summarize, and appraise evidence from the literature for the use of cholinesterase inhibitors and memantine in the treatment of cognitive symptoms in patients with HD. Methods: A searched was conducted in PubMed and SCOPUS, from inception until February 2024, for Randomized Clinical Trials (RCTs), open-label, and case-control studies. Quality appraisal was performed using ROBINS-I and ROB2 for non-randomized studies and RCTs, respectively. Results: Five eligible studies (three RCTs, one extension study, and one retrospective case-control), exploring the use of rivastigmine (n = 3), memantine (n = 1), and donepezil (n = 1) were found. Only two had a follow-up period longer than eight months. Previous cognitive functioning was not specified in three out of five studies. Cognitive measures varied widely, with Unified Huntington's Disease Rating Scale and Mini-Mental State Exam being used more frequently. None of the studies showed a significant improvement in cognitive function. Side effects occurred in up to 50% of patients and were usually considered mild. Conclusions: There is insufficient evidence in the literature to support the use of cholinesterase inhibitors or memantine for cognitive symptoms in patients with HD.
- Open Access
- 7 November 2024
- Published by Sociedade Portuguesa de Neurologia in Sinapse
- Vol. 24 (3) , 122-127
Ampliando o Espectro da Cefaleia Hípnica: Um Estudo de Coorte Retrospetivo
Introdução: A cefaleia hípnica é uma entidade rara que requer crises estritamente relacionados ao sono. Contudo, existem doentes com cefaleias noturnas recorrentes que apresentam ocasionais crises em vigília e que são excluídos desse diagnóstico. O nosso objetivo foi comparar esses dois grupos de doentes e compreender se as suas diferenças justificam um diagnóstico distinto. Métodos: Trata-se de um estudo de coorte retrospetivo, comparativo, entre doentes com cefaleia recorrente predominantemente noturna (≥80% das crises) (PNRH) e cefaleia hípnica (HH) seguidos numa clínica terciária de cefaleias. Resultados: Foram incluídos 31 doentes (83,9% mulheres), dos quais 13 com PNRH e 18 HH (13 casos com HH provável e 5 HH definitiva). Não houve diferenças significativas entre os grupos quer na demografia quer nas características da dor e resposta ao tratamento. Ambos tinham uma frequência elevada (71%) de crises prévias de enxaqueca e 51,7% preenchiam os critérios para uso excessivo de medicamentos. Conclusão: Estes resultados sugerem que existe uma sobreposição entre a cefaleia hípnica e a cefaleia recorrente predominantemente noturna. Ambas podem evoluir a partir de enxaqueca. Embora a sua fisiopatologia permaneça desconhecida, a cefaleia noturna recorrente pode ser outra forma provável de cefaleia hípnica.
- 7 November 2024
- Published by Sociedade Portuguesa de Neurologia in Sinapse
- Vol. 24 (3) , 122-127
Open AccessAmpliando o Espectro da Cefaleia Hípnica: Um Estudo de Coorte Retrospetivo
Introdução: A cefaleia hípnica é uma entidade rara que requer crises estritamente relacionados ao sono. Contudo, existem doentes com cefaleias noturnas recorrentes que apresentam ocasionais crises em vigília e que são excluídos desse diagnóstico. O nosso objetivo foi comparar esses dois grupos de doentes e compreender se as suas diferenças justificam um diagnóstico distinto. Métodos: Trata-se de um estudo de coorte retrospetivo, comparativo, entre doentes com cefaleia recorrente predominantemente noturna (≥80% das crises) (PNRH) e cefaleia hípnica (HH) seguidos numa clínica terciária de cefaleias. Resultados: Foram incluídos 31 doentes (83,9% mulheres), dos quais 13 com PNRH e 18 HH (13 casos com HH provável e 5 HH definitiva). Não houve diferenças significativas entre os grupos quer na demografia quer nas características da dor e resposta ao tratamento. Ambos tinham uma frequência elevada (71%) de crises prévias de enxaqueca e 51,7% preenchiam os critérios para uso excessivo de medicamentos. Conclusão: Estes resultados sugerem que existe uma sobreposição entre a cefaleia hípnica e a cefaleia recorrente predominantemente noturna. Ambas podem evoluir a partir de enxaqueca. Embora a sua fisiopatologia permaneça desconhecida, a cefaleia noturna recorrente pode ser outra forma provável de cefaleia hípnica.